<DOC>
	<DOCNO>NCT02366091</DOCNO>
	<brief_summary>The investigator study whether anti-inflammatory agent improve abnormal coronary artery function patient coronary artery disease ( CAD ) abnormal coronary artery function .</brief_summary>
	<brief_title>Inflammation Coronary Endothelial Function</brief_title>
	<detailed_description>Sometimes , patient coronary artery disease ( CAD ) , even though blood pressure control , patient cholesterol medication , smoking , eat properly normal level physical activity ; investigator still see development new blockage , progression exist blockage , sometimes even clinical event like heart attack stroke . Therefore , investigator always try find additional way decrease progression exist blockage prevent new one . What investigator study program function coronary artery particular inner line artery call endothelium . It several important function ; one condition stress release substance call nitric oxide increase size artery increase blood flow . When function normally artery increase much blood flow increase stress . The investigator study coronary artery function magnetic resonance imaging , MRI . MRI method obtain image happen inside body . MRI involve radiation , x-ray , injection contrast . The investigator measure flow artery dimension artery rest handgrip stress learn extent artery dilate flow increase stress . The investigator believe inflammation interfere normal function decrease inflammation abnormal endothelial function may improve . Methotrexate colchicine anti-inflammatory agent approve Food Drug Administration ( FDA ) treat arthritis condition . These drug approve use suppress inflammation patient coronary artery disease improve coronary artery endothelial function . The FDA allow use methotrexate , colchicine and/or combination research study . This study involve 24 week anti-inflammatory drug 3 Magnetic Resonance Imaging ( MRI ) scan heart study procedure .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Participants either gender 21 year age ( upper age limit ) , History prior myocardial infarction ( MI ) , coronary revascularization , coronary angiography multidetector compute tomography ( MDCT ) demonstrate least one coronary artery ≥50 % luminal stenosis plan revascularization , Clinically stable 3 month , Evidence inflammation manifest elevated hsCRP ( &gt; 2mg L1 ) Abnormal coronary endothelial function ( change CSA IHE ≤0 % rest value : mean decrease CSA change ( 0 % ) baseline IHE ) , Permission patient 's clinical attending physician , Patients treat statin . Patients unable understand risk , benefit , alternative participation give meaningful consent , Patients contraindication MRI implant metallic object ( preexist cardiac pacemaker , cerebral clip ) indwell metallic projectile , Acute coronary syndrome within prior six month , Pregnant woman , Contraindications methotrexate colchicine outline American College Rheumatology ; include active bacterial infection , tuberculosis , herpes zoster infection , leukopenia ( &lt; 5000/mm3 ) , thrombocytopenia ( &lt; 150,000/mm3 ) , elevation hepatic transaminase ( &gt; 2x upper limit normal ) , hepatitis B C , moderate renal disease ( estimate creatine clearance &lt; 45ml/min ) , plan surgery , Chronic inflammatory condition lupus rheumatoid arthritis , ulcerative colitis Crohn 's disease , Interstitial lung disease pulmonary fibrosis , HIV positive , Requirement , intolerance , methotrexate colchicine , History nonbasal cell malignancy treatment lymphoproliferative disease past 5 year , Requirement use drug alter folate metabolism , History alcohol abuse unwillingness limit consumption &lt; 4 drink per week , Women childbearing potential ( even use oral contraceptive agent ) intention breastfeed . Men plan father child study period , Chronic use oral IV steroid therapy immunosuppressive biologic response modifier , History chronic pericardial effusion , pleural effusion ascites , New York Heart Association Class IV heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>